Literature DB >> 1652374

Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA.

J Friedman1, I Weissman.   

Abstract

We report the cloning and characterization of a new binding protein for the immunosuppressive drug cyclosporin A (CsA). This new cyclophilin, cyclophilin C (cyp C), shows extensive homology with all previously identified cyclophilins. Cyp C mRNA is expressed in a restricted subset of tissues relative to cyclophilins A and B, but is present in those tissues reported to be most affected by CsA therapy. A cyp C fusion protein has peptidyl-prolyl isomerase activity, and CsA inhibits this activity. Using the cyp C fusion protein as an affinity ligand to probe cellular extracts, we find that the cyp C fusion protein binds specifically to a 77 kd protein in the absence of CsA, while in the presence of CsA it instead binds specifically to a 55 kd protein. We propose that the p77 is involved in cyp C native function and that the p55 is involved in signal transduction events blocked by treatment with immunosuppressive levels of CsA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652374     DOI: 10.1016/0092-8674(91)90123-g

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  95 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

2.  FKBP12 physically and functionally interacts with aspartokinase in Saccharomyces cerevisiae.

Authors:  C M Alarcón; J Heitman
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  Overexpression, purification, and characterization of yeast cyclophilins A and B.

Authors:  L D Zydowsky; S I Ho; C H Baker; K McIntyre; C T Walsh
Journal:  Protein Sci       Date:  1992-08       Impact factor: 6.725

4.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

5.  The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin.

Authors:  Y J Jin; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae.

Authors:  J Heitman; A Koller; J Kunz; R Henriquez; A Schmidt; N R Movva; M N Hall
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

Review 7.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

8.  Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.

Authors:  Songkai Liu; Maria Asparuhova; Vincent Brondani; Ingrid Ziekau; Thomas Klimkait; Daniel Schümperli
Journal:  Nucleic Acids Res       Date:  2004-07-14       Impact factor: 16.971

9.  Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis.

Authors:  Weinong Han; Keyoumars Soltani; Mei Ming; Yu-Ying He
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

10.  Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells.

Authors:  N Toyota; Y Hashimoto; S Matsuo; Y Kitamura; H Iizuka
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.